Log in or register to see all Alerts
New HTA Decisions in France
December 2019
Drug name
CROMOPTIC (sodium cromoglicate)
Company
Chauvin
Decision date
06/11/2019
Therapeutic area
Eye conditions
Therapeutic sub area
Eye conditions: general and other
Official notice date
18/11/2019
Reimbursement %
Decision (SMR)
Moderate
Decision (ASMR)
No improvement (V)
Indication
CROMOPTIC is indicated for the symptomatic treatment of allergic eye disease.
Decision Type
New technology assessment
Summary
The committee considered the actual benefit of CROMOPTIC to be 'moderate' in the indication of the Marketing Authorisation. It was concluded that CROMOPTIC 2% eye drops in solution in a 10 ml vial does not provide any improvement in the medical service rendered (ASMR V) compared to other presentations of CROMOPTIC 2% eye drops in solution already listed.